John Crowley, Amicus CEO (via YouTube)
January 11, 2022 06:49 AM ESTUpdated 07:00 AM
Bioregnum
Cell/Gene Tx

Am­i­cus gets hit with an 'un­ex­pect­ed' set­back on a gene ther­a­py tapped to lead $600M SPAC spin­out

Am­i­cus has tak­en the axe and chopped a gene ther­a­py for Bat­ten dis­ease out of the pipeline af­ter an “un­ex­pect­ed” set­back in the clin­ic. …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Judge halts some NIH cuts af­ter 22 states sue

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times